SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike rallied with cybersecurity peers as reports of critical PHP vulnerabilities and related service disruptions heightened concern about AI-enabled cyber threats and demand for protection. Traders welcomed the sectors strength, while skeptics argued the move may be hype given the stocks stretched valuation.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced 2026 outlook, and suspended dividend to prioritize debt reduction have driven heavy selling; management attributed the slump to recession-level appliance demand and the Iran war. Traders are debating whether the decline reflects a temporary demand shock or deeper problems with the companys debt, execution, and management, while some see the selloff as a contrarian buying opportunity.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

ESMO subgroup survival data for RASONQUE and the start of a Phase 3 zoldonrasib trial are fueling discussion, alongside early results from a vopimetostat combination with Revolution Medicines RAS inhibitor. Traders debate whether RASONQUE can maintain its lead as rivals advance, weighing concerns about weaker responses in the KRAS G12D subgroup against reported survival benefits and combination potential.

Cash Cat

CASHCAT is drawing attention for its sharp, volatile swings after a major rally and steep pullbacks, with traders debating whether dips are buying opportunities or signs of a pump-and-dump. Bulls point to its Robinhood-chain and meme-coin ecosystem narrative, while skeptics question its utility and warn of further losses; claims of manipulation and short squeezes remain speculation.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Toshibas plan to expand hard-drive capacity has raised fears that added competition could weaken Seagates pricing power, prompting sharp swings in STX alongside Western Digital. Traders are divided: some see a lasting threat to the storage-scarcity thesis, while others view the selloff as an overreaction given the long ramp-up and strong AI data-center demand.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars sharp pullback ahead of its quarterly report is driving debate, despite traders pointing to a record backlog and data-center power demand. Some see an oversold buying opportunity, while others expect further weakness if results or guidance fail to meet high expectations.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARKK is drawing attention for a tentative rebound and attempts to break out of a prolonged, volatile base, with bullish traders pointing to improving momentum and renewed interest in growth stocks. Others remain skeptical, citing the funds past underperformance and Cathie Woods portfolio decisions.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is drawing attention amid a broader market pullback, with traders debating whether weakness tied to inflation, elevated yields and geopolitical oil risks could deepen or prove temporary. Bearish crash warnings contrast with dip-buying and long-term investors who view index declines as accumulation opportunities.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs earnings have sparked debate after shares sold off despite improving profitability and cash flow: bulls view the reaction as excessive and cite the companys cash, buybacks and low valuation, while bears focus on declining revenue and weak Chinese consumer demand. The discussion also reflects persistent caution toward Chinese equities and uncertainty over whether JD can turn better margins into renewed growth.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods upcoming Q3 earnings report is the dominant focus, with traders debating whether event-contract revenue can offset weaker crypto activity and slower growth. Optimism about a strong report competes with concern over the sharp selloff, insider-sale speculation, and sensitivity to crypto and broader market weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months

Equity

European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.


Viking’s Key Obesity Pill Enters Phase 3 Trial –  Here’s What Investors Need To Know 

Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.


Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win 

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding

Lilly’s Foundayo 17.2 mg achieved a 1.5% greater weight loss and a 0.3% greater reduction in A1C than oral semaglutide 25 mg after 52 weeks.


VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff 

Viking Therapeutics priced an upsized financing deal at a 16% discount from the stock’s closing price on Wednesday.


VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance 

Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.


Novo Nordisk Targets Over Five New Blockbusters By 2030, But NVO Stock Slides On Growth Concerns 

Novo Nordisk’s long-term growth targets failed to ease investor concerns over Eli Lilly’s obesity-drug lead, CagriSema’s comparative performance and upcoming semaglutide patent expirations.


Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know

Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.


NVO To Present Fresh Data From Blockbuster Wegovy Pill At European Conference As Rival Eli Lilly Readies Its Own Obesity Updates

Novo said it will present 44 abstracts at the European Association for the Study of Diabetes symposium later this month.


NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity 

Morgan Stanley downgraded Novo to ‘Underweight’ from ‘Equal Weight’ while keeping its $40 price target, a 7% downside from current levels.


Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The EMA’s advisory committee recommended approving Foundayo for adults with obesity or those who are overweight and have related health conditions.</li><li>The committee also backed its use in adults with type 2 diabetes.</li><li>Foundayo generated $98 million in Q2 revenue.</li></ul><p>Eli Lilly (LLY) received a boost to its European business after the European Medicines Agency’s (EMA) advisory committee recommended approval of its once-daily weight-loss pill, Foundayo, on Friday.</p><p>The recommendation comes as Lilly looks to build on the success of its blockbuster weight-loss treatments, Mounjaro and Zepbound.</p><p><a class="mention" data-mention="$LLY" data-symbol-id="LLY" href="https://stocktwits.com/symbol/LLY" target="_blank">LLY shares</a> were up 1.8% at the time of writing. The stock has gained about 7.8% so far this week, heading for its best weekly gain in nearly four months.</p><h2 class="st-heading-2">Foundayo Moves Closer To European Launch</h2><p>The EMA’s Committee for Medicinal Products for Human Use recommended approving Foundayo for adults with obesity or those who are overweight and have related health conditions. The committee also backed its use in adults with type 2 diabetes.</p><p>Foundayo contains Orforglipron, which helps control blood sugar and reduce appetite. Unlike some oral GLP-1 treatments, it can be taken without food or water restrictions.</p><p>The pill is already available in the U.S., the U.K. and the United Arab Emirates. In the U.S., it received FDA approval in April for weight management, while in the U.K., it received<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes?utm_source=chatgpt.com"> approval</a> in August for both weight management and type 2 diabetes.</p><h2 class="st-heading-2">What Happens Next?</h2><p>Foundayo still requires final authorization from the European Commission, which generally issues a decision within 67 days of EMA’s recommendation. While the timeline puts a potential decision around late December, Lilly has not confirmed when commercial sales would begin.</p><p>Foundayo generated $98 million in second-quarter (Q2) revenue. However, Lilly's two blockbuster drugs generated far more. In Q2, Mounjaro generated $9.94 billion in sales, up 91% year over year, while Zepbound brought in $4.93 billion, up 46%.</p><h2 class="st-heading-2">Retail Says LLY Is Breaking Out</h2><p>Retail sentiment surrounding LLY on Stocktwits turned ‘neutral’ from ‘bearish’ over the past 24 hours, though message volumes remained ‘normal.’</p><p>One user noted that LLY stock is breaking out.</p><p><stembedurl>https://stocktwits.com/Jamtrades/message/666690626</stembedurl></p><p>LLY shares have gained more than 18% so far this year, significantly outperforming rival Novo Nordisk (NVO), whose shares have slumped more than 25% over the same period.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.

Lilly(Eli) & Co

Roundhill GLP-1 & Weight Loss ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$29.64
Prev Close	$29.98
Open	$29.78
Dividend Yield	N/A
50-Day Moving Average	$31.47
Beta	N/A
Avg. Volume	15,973.61
PE Ratio	N/A

52-Week High	$37.15
52-Week Low	$27.60
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

OZEM Fundamentals